Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
FLT3

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

FLT3

Chemical Structure Cat. No. Product Name CAS No.
HM43239 Chemical Structure
 BCP40967 HM43239 2569527-64-4
HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations.
SB1317 Chemical Structure
 BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
CA-4948 Chemical Structure
 BCP33271 CA-4948 1801344-14-8
CA-4948 is a potent IRAK4/FLT3 inhibtor with anti-tumor activity.
UNC2025 hydrochloride Chemical Structure
 BCP36467 UNC2025 hydrochloride 2070015-17-5
UNC-2025 hydrochloride is the hydrochloride salt of UNC-2025, which is the Mer/FLT3 dual inhibitor.
TG-89 Chemical Structure
 BCP35054 TG-89 936091-56-4
TG-89 is an inhibitor of JAK2, FLT3, RET and JAK3.
Crotonoside Chemical Structure
 BCP34471 Crotonoside 1818-71-9
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML.
Donafenib Chemical Structure
 BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
FF-10101 Chemical Structure
 BCP23613 FF-10101 FF-10101
FF-10101 is a novel irreversible FLT3 inhibitor, shows excellent efficacy against AML cells with FLT3 mutations
MRX-2843 Chemical Structure
 BCP30180 MRX-2843 1429882-07-4
MRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3.
TG46 Chemical Structure
 BCP28052 TG46 936091-15-5
TG-46 is an inhibitor of JAK2, FLT3, RET, JAK3.
123下一页末页共 49 条记录 1 / 5 页 
0086-15971444841